Member Info for violindog

Spre….agree.. we don’t know the final details but investors only need to consider the quality of Redmile and Vulps (who recently added considerably) and the track record of the new CFO, David , as per the April RNS below. Add to that the progression free survival of iSCIB and I don’t think too many current and potential investors will share your “uncertainty”. I think that the writing is clearly on the wall….full steam ahead with a bright future on the NASDAQ

Spre…don’t know why you guys fear Monday and expect a fall. We went from around -13% to recover strongly post the “forced” confirmation RNS from Sclp.

Just before the close we had recovered all the days losses and fell 3.16% on the last few trades.

NASDAQ is the turkey to finance and this is a positive move. Just a shame someone squealed before the finalised deal.

Says everything really …. I wonder if negotiations were going on before his appointment , due to the timeline I guess that they were??

Dr Phil L'Huillier, CEO of Scancell, said: "David brings broad and strategic financing expertise to Scancell and will be a strong interim CFO, ensuring continuity and progress in our strategy. We remain laser focused on delivering iSCIB1+ to patients and building shareholder value. Having David in place enables us to seamlessly advance our constructive financing and partnering discussions on our lead ImmunoBody® iSCIB1+, now with the recently obtained strong regulatory feedback in hand. Further, David brings valuable investor engagement and strategic financing expertise, including Nasdaq listing experience that will help guide the company as we explore a potential listing in the US."

The company would need to rename from Neuphoria to Scancell??

Neuphoria share price is now currently-0.4% so I guess there’s going to be no premium to the takeover price

LONDON - Scancell Holdings plc (AIM:SCLP) confirmed today it is in advanced discussions with Neuphoria Therapeutics Inc. regarding a potential reverse merger transaction, according to a press release statement.

Under the proposed deal, Scancell would acquire Neuphoria through an all-share transaction. The company said the reverse merger could facilitate a Nasdaq listing, which it believes could increase its profile with U.S. specialist investors.

Scancell, a clinical stage biotechnology company developing immunotherapies to treat cancer, is also in discussions regarding possible equity and debt financing to support a planned global Phase 3 registrational study for its lead asset, iSCIB1+.

The potential acquisition and associated financing remain subject to final terms and definitive documentation. The company stated there is no certainty that a firm agreement between Scancell and Neuphoria will be reached, nor certainty over the quantum and terms of associated financing.

Scancell said the potential transaction is not anticipated to constitute a reverse takeover for the purpose of the AIM Rules for Companies.

Neuphoria is a Nasdaq-listed biotechnology company focused on developing therapies for neuropsychiatric disorders.

Phillip L’Huiller, Chief Executive Officer of Scancell, was responsible for arranging the release of the announcement. The company said further announcements will be made as appropriate in due course.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

NEUP now rising pre market + 5.5 %

EE…that would have to be so news to lift us from 17p to get away with a 25p placing.

Clearnerworld

This is the link

https://x.com/MarkKleinmanSky/status/2070438569517125709?s=20

Hasn’t moved “pre market” and no announcements currently.

Caiskin…yes..hopefully 🤞

Guess Redmile / Vulps are controlling / deciding how this will play out and when they are ready we will be told. The Sky guy who tweeted does appear well connected and his track record is ok.

A NASDAQ listing is the way forward to unlocking both value and funding but still unbelievable that BMS et al haven’t settled this …everyone has a price so they say .

The tweet said Scancell declined to comment….so Scancell know it’s leaked if true. It will be very interesting to watch if NEUP make any pre market statement…if so ..Scancell will surely have to follow by an RNS today .

Second bit of the article…

Additionally, Neuphoria disclosed that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP on November 10, 2025. The fund expressed interest in acquiring all outstanding shares it doesn’t already own for $5.20 per share in cash. Lynx1 also indicated its intent to nominate individuals for election to Neuphoria’s Board of Directors at the company’s 2025 Annual Meeting of Stockholders scheduled for December 12, 2025.

The company’s Board of Directors stated it will evaluate the Lynx1 offer as part of its broader strategic review. Neuphoria emphasized that no timeline has been established for the strategic evaluation process and noted that there is no guarantee that the process will result in any transaction being announced or completed.

From November 2025

Investing.com -- Neuphoria Therapeutics (NASDAQ:NEUP) the clinical-stage biotechnology company announced it has initiated a strategic review to maximize stockholder value.

The company, which focuses on developing treatments for neuropsychiatric disorders, is considering various strategic alternatives including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements. Neuphoria has engaged H.C. Wainwright & Co. as its exclusive financial advisor to assist with the evaluation process.

Thanks Rat….settled my nerves 😂

Still feels like a deal is happening…surely management have left it too late for anything else.

All logic indicates stay firm but you can’t blame folks for being nervous. Scancell doesn’t have the greatest record for sticking to timelines and Phil is a prior mastermind at raising funds .

A great positive (despite the Trinity note ) ..there hasn’t been any investor presentations etc so perhaps there won’t be a fundraiser after all ??

Quoth, yes ..currently that’s the sell price quoted ATM. SP being chipped away and this news limbo doesn’t help at all.

MHRA only need to look at who is sitting on Scancells advisory panel….if they ask for external “advice” they need a reality check.

Another reason China will become the dominant biotech “go to” country. Personally…even as the chief moaner …I would support a fundraising to rid us of AIM and the UK regulatory system.